KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Royalty Pharma (RPRX) over the last 5 years, with Dec 2024 value amounting to $594.1 million.

  • Royalty Pharma's Shares Outstanding (Diluted Average) fell 4.86% to $566.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $566.8 million, marking a year-over-year decrease of 4.86%. This contributed to the annual value of $594.1 million for FY2024, which is 1.46% down from last year.
  • Per Royalty Pharma's latest filing, its Shares Outstanding (Diluted Average) stood at $594.1 million for FY2024, which was down 1.46% from $602.9 million recorded in FY2023.
  • Royalty Pharma's 5-year Shares Outstanding (Diluted Average) high stood at $602.9 million for FY2023, and its period low was $375.5 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $545.0 million, with a median of $594.1 million in 2024.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 37.66% in 2023, then declined by 1.46% in 2024.
  • Yearly analysis of 5 years shows Royalty Pharma's Shares Outstanding (Diluted Average) stood at $375.5 million in 2020, then grew by 10.48% to $414.8 million in 2021, then rose by 5.59% to $438.0 million in 2022, then soared by 37.66% to $602.9 million in 2023, then dropped by 1.46% to $594.1 million in 2024.